Ayaka Matsuoka

Dr. Ayaka Matsuoka

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AMAyaka Matsuoka
Ayaka Matsuoka
SYShodai Yoshihiro
Shodai Yoshihiro
HSHaruka Shida
Haruka Shida
GAGen Aikawa
Gen Aikawa
YFYoshihisa Fujinami
Yoshihisa Fujinami
SIShigeaki Inoue
Shigeaki Inoue
Previous systematic review and meta-analysis indicates that rehabilitation within a week of intensive care unit (ICU) admission benefits physical function in critically ill patients. This updated systematic review and meta-analysis aim to clarify effects of initiating rehabilitation within 72 h of ICU admission on long-term physical, cognitive, and mental health. We systematically searched the MEDLINE, Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi for randomized controlled trials (RCTs) between April 2019 and November 2022 to add to the previous review. Two investigators independently selected and extracted data. Pooled effect estimates for muscle strength, cognitive function, mental health after discharge, and adverse events were calculated. Evidence certainty was assessed via Grading of Recommendations, Assessment, Development, and Evaluations. Eleven RCTs were included in the meta-analysis. Early rehabilitation may improve muscle strength (three trials; standard mean difference [SMD], 0.16; 95% confidence interval [CI], −0.04–0.36) and cognitive function (two trials; SMD, 0.54; 95% CI, −0.13–1.20). Contrastingly, early mobilization showed limited impact on mental health or adverse events. In summary, initiating rehabilitation for critically ill patients within 72 h may improve physical and cognitive function to prevent post-intensive care syndrome without increasing adverse events. The effect on mental function remains uncertain.

7 November 2022 in The Journal of Clinical Psychiatry
Verified
Journal Article
Open access
PDF file
AMAyaka Matsuoka
Ayaka Matsuoka
STShuko Tobita
Shuko Tobita
RSRintaro Sogawa
Rintaro Sogawa
KSKota Shinada
Kota Shinada
TMToru Murakawa-Hirachi
Toru Murakawa-Hirachi
YSYuichiro Sakamoto
Yuichiro Sakamoto
The novel dual orexin receptor antagonists (DORAs) suvorexant and lemborexant may be helpful in preventing delirium. This study examined the efficacy of these two DORAs in preventing delirium in critically ill patients at an advanced critical care center.

31 March 2023 in General Hospital Psychiatry
Verified
Journal Article
Open access
AMAyaka Matsuoka
Ayaka Matsuoka
RSRintaro Sogawa
Rintaro Sogawa
TMToru Murakawa-Hirachi
Toru Murakawa-Hirachi
YMYoshito Mizoguchi
Yoshito Mizoguchi
AMAkira Monji
Akira Monji
YSYuichiro Sakamoto
Yuichiro Sakamoto
ICU delirium reportedly contributes to increased mortality attributed to underlying diseases, long-term cognitive decline, and increased healthcare costs. Dual orexin receptor antagonists (DORAs), suvorexant and lemborexant, have been suggested for preventing ICU delirium. Although ventilator management is a risk factor for delirium, no study has examined the efficacy of suvorexant and lemborexant in preventing delirium in critically ill patients requiring ventilation. Thus, we retrospectively evaluated the efficacy of DORA in preventing delirium in critically ill adult patients requiring ventilatory management in the emergency room. This retrospective study included patients aged ≥18 years who were admitted to the emergency room and received ventilator support between January 2015 and April 2022. The HR (95% CI) for delirium development in patients taking DORA was estimated using a Cox proportional hazards model, which was adjusted for the patient background and concomitant medications. HRs were calculated for patients taking suvorexant and those taking lemborexant using a stratified analysis. Of the 297 patients included in the study, 67 were in the DORA group; 50 were on suvorexant and 17 were on lemborexant. The DORA group had a lower incidence of delirium than the control group (p < 0.0001). The risk of delirium was lower in the DORA group compared the control group (HR, 0.22; 95% CI 0.12-0.40).The risk of developing delirium was lower with suvorexant (HR 0.22; 95% CI 0.11-0.41) and lemborexant (HR 0.25; 95% CI 0.08-0.81). DORA is a promising drug that could have the potential to prevent delirium, and its efficacy in preventing delirium should be tested in randomized controlled trials in the future.

28 November 2022 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
AMAyaka Matsuoka
Ayaka Matsuoka
HKHiroyuki Koami
Hiroyuki Koami
KSKota Shinada
Kota Shinada
YSYuichiro Sakamoto
Yuichiro Sakamoto
Background: The severe acute respiratory syndrome coronavirus 2 Omicron variant has a low rate of serious illness, is highly contagious, and has spread rapidly since January 2022. The number of severe cases and deaths remains problematic. Here, we aimed to elucidate the coagulation pathology of Omicron‐infected patients using rotational thromboelastometry.Methods: Patients with coronavirus disease 2019, hospitalized and treated from January 2021 to April 2022, were included. The Alpha–Delta and Omicron groups were defined during admission. Blood tests, clinical course, and rotational thromboelastometry measurements were compared using a propensity score‐matched cohort.Results: Both groups had 21 patients each. Lactate dehydrogenase (Alpha–Delta group [interquartile range] vs. Omicron group [interquartile range]; 449 [368–518] U/L vs. 241 [196–398] U/L, p = 0.01) and ferritin (1428 [1145–3061] ng/dl vs. 481 [188–881] ng/dl, p = 0.0002) levels were significantly lower in the Omicron group. In rotational thromboelastometry, the thrombus hardness indexes FIBTEM A5 (29 [23–34] mm vs. 23 [18–28] mm, p = 0.034) and maximum clot firmness (34 [27–40] mm vs. 26 [21–33] mm, p = 0.021) were significantly lower in the Omicron group, whereas the fibrinolysis index FIBTEM LI60 (98 [92–100] % vs. 100 [100–100] %, p = 0.0082) was higher.Conclusion: Severe coagulation abnormalities may be less likely in Omicron‐infected patients than in those infected with the previous Alpha and Delta variants.

29 November 2021 in Trauma Surgery & Acute Care Open
Verified
Journal Article
Open access
PDF file
AMAyaka Matsuoka
Ayaka Matsuoka
TMToru Miike
Toru Miike
MMMariko Miyazaki
Mariko Miyazaki
TGTaku Goto
Taku Goto
ASAkira Sasaki
Akira Sasaki
YSYuichirou Sakamoto
Yuichirou Sakamoto
Background Delirium has been shown to prolong the length of intensive care unit stay, hospitalization, and duration of ventilatory control, in addition to increasing the use of sedatives and increasing the medical costs. Although there have been a number of reports referring to risk factors for the development of delirium, no model has been developed to predict delirium in trauma patients at the time of admission. This study aimed to create a scoring system that predicts delirium in trauma patients. Methods In this single-center, retrospective, observational study, trauma patients aged 18 years and older requiring hospitalization more than 48 hours were included and divided into the development and validation cohorts. Univariate analysis was performed in the development cohort to identify factors significantly associated with prediction of delirium. The final scoring system for predicting delirium was developed using multivariate analysis and internal validation was performed. Results Of the 308 patients in the development cohort, 91 developed delirium. Clinical Frailty Score, fibrin/fibrinogen degradation products, low body mass index, lactate level, and Glasgow Coma Scale score were independently associated with the development of delirium. We developed a scoring system using these factors and calculated the delirium predictive score, which had an area under the curve of 0.85. In the validation cohort, 46 of 206 patients developed delirium. The area under the curve for the validation cohort was 0.86, and the calibration plot analysis revealed the scoring system was well calibrated in the validation cohort. Discussion This scoring system for predicting delirium in trauma patients consists of only five risk factors. Delirium prediction at the time of admission may be useful in clinical practice. Level of evidence Prognostic and epidemiological, level III.

24 September 2022 in Trials
Verified
Journal Article
Open access
PDF file
AEAkira Endo
Akira Endo
Kazuma YamakawaKazuma Yamakawa
Kazuma Yamakawa
TTTakashi Tagami
Takashi Tagami
YUYutaka Umemura
Yutaka Umemura
KTKyosuke Takahashi
Kyosuke Takahashi
YOYasuhiro Otomo
Yasuhiro Otomo
Background: Hemodynamic stabilization is a core component in the resuscitation of septic shock. However, the optimal target blood pressure remains debatable. Previous randomized controlled trials suggested that uniformly adopting a target mean arterial pressure (MAP) higher than 65 mmHg for all adult septic shock patients would not be beneficial; however, it has also been proposed that higher target MAP may be beneficial for elderly patients, especially those with arteriosclerosis. Methods: A multicenter, pragmatic single-blind randomized controlled trial will be conducted to compare target MAP of 80–85 mmHg (high-target) and 65–70 mmHg (control) in the resuscitation of septic shock patients admitted to 28 hospitals in Japan. Patients with septic shock aged ≥65 years are randomly assigned to the high-target or control groups. The target MAP shall be maintained for 72 h after randomization or until vasopressors are no longer needed to improve patients’ condition. To minimize the adverse effects related to catecholamines, if norepinephrine dose of ≥ 0.1 μg/kg/min is needed to maintain the target MAP, vasopressin will be initiated. Other therapeutic approaches, including fluid administration, hydrocortisone use, and antibiotic choice, will be determined by the physician in charge based on the latest clinical guidelines. The primary outcome is all-cause mortality at 90 days after randomization. Discussion: The result of this trial will provide great insight on the resuscitation strategy for septic shock in the era of global aged society. Also, it will provide the better understanding on the importance of individualized treatment strategy in hemodynamic management in critically ill patients. Trial registration: UMIN Clinical Trials Registry; UMIN000041775. Registered 13 September 2020.